Skip to main content
Premium Trial:

Request an Annual Quote

SYN X Lures New Proteomics Pick

Premium

Be careful whom you send out for customer service. Brad Thatcher, formerly at California-based Ciphergen Biosystems, placed an instrument at SYN X Pharma in Toronto a little more than a year ago. After continued work with the customer resulting in “very exciting data,” Thatcher finally went back to SYN X — and stayed.

“There was a lot of room for exploration and growth,” says SYN X’s new vice president of proteomics discovery. The company gave Thatcher the chance to “use all the proteomics knowledge I had, rather than just the small corner of it that Ciphergen concentrated on.”

Thatcher, a native Canadian who was lured to the US by higher salaries, got his start in the field about 11 years ago. “It was at that time called protein chemistry and done by people in basement labs,” he recalls.

Now, he focuses on Syndrome X, which includes symptoms of hypertension, renal failure, diabetes, and stroke, among others. “My job is to take apart sera and affected tissues and find out what is changing in them at the protein level, and what pathways are affected.”

The goal is to discover markers that differentiate the stages of a disease and enable better patient classification and treatment.

Meanwhile, Thatcher is accomplishing some personal goals. Three weeks after heading to Toronto, he found an apartment. “I have shelter now,” he says gleefully, “which is a big step from yesterday.”

— Meredith Salisbury

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.